NFKB1 and COVID-19: Moreover, the persistent inflammatory state seen in long COVID‐19 patients may be modulated by SIRT1′s ability to suppress NF‐κB signaling and promote regulatory T cell function [3, 86], while its capacity to counteract viral‐induced epigenetic modifications could reverse the long‐term immune reprogramming associated with SARS‐CoV‐2 infection [87].